Yes, let's all read it again.
Post 24889 states as fact: “LC SENTINEL is a combination of Radient's DR-70 and Provista's BT Test..”
I responded in post 24928 with “False, LC Sentinel is a Lung Cancer test and Provista’s BT Test is specific to cancer only. Provista’s LC Sentinel is not a combination of DR70 and the BT Test."
Post 24936 responded with “You might want to read it again..The news article says it is a combination...Capiche..Wolfie ahooooooooooooo,” followed by the 2010 news article below.
I want to Capiche. Somebody please tell me where the 2010 news article below even *mentions* LC Sentinel. Because when I read Provista’s news articles, including the one below, I find that (1) Provista’s LC Sentinel is just another name for DR70, not combined with anything else, and (2) regarding the BT Test: they tried to integrate Radient’s DR70 into their BT Test in 2010 as described below, but after further testing they abandoned the use of DR70 in ALL their products. Shortly afterwards, William Gartner left Provista.
Here is the news article cited in post 24936:
TUSTIN, CA, May 04 (MARKET WIRE) --
Through its US-based subsidiary AMDL Diagnostics Inc., Radient
Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today
diagnostics development and commercialization firm Provista Life Sciences
LLC (PLS) has independently validated Radient Pharmaceuticals' Onko-Sure
in vitro diagnostic (IVD) cancer test as a potential screening tool for
breast cancer detection.
RPC's Onko-Sure product validation follows PLS' completion of a phase I,
37 subject trial to provide a preliminary evaluation of the use of
Radient's Onko-Sure test as a complement to Provista's existing BT Test
breast cancer screen. The Phase I trial was run by Provista in the
company's Arizona-based CLIA laboratory.
"We are extremely pleased with the initial results," said William
Gartner, President and CEO of Provista. "We are dedicated to improving
women's health and the early detection of breast cancer and RPC's
Onko-Sure IVD cancer test may help our BT Test achieve even higher levels
of accuracy, particularly for women over 50 where Onko-Sure showed strong
differentiation between women with breast cancer versus controls."
RPC's Onko-Sure IVD test is a simple, non-invasive, patent-pending and
regulatory-approved test for use as an aid in early detection of cancer.
Onko-Sure enables physicians and their patients to effectively monitor
and/or detect certain types of cancers by measuring the accumulation of
specific breakdown products in the blood called Fibrin and Fibrinogen
Degradation Products (FDP). FDP levels rise dramatically with the
progression of cancer. Onko-Sure is approved by the US FDA for the
monitoring of colorectal cancer, Health Canada as a lung cancer screen
and cancer monitoring tool, and the European Union, Indian government,
Korean government, and Taiwanese government as a cancer monitoring or
cancer screening test.
Provista's BT Test, or Biomarker Translation Test, measures the molecular
level of specific proteins in the blood and, by using a proprietary
relational software program developed by Provista, a comprehensive report
is generated providing the healthcare provider with the individual
concentration levels of each of these proteins markers along with a
singular test score, called the BT Score, which an indicator of breast
cancer presence or absence. The BT Test is greater than 95% accurate in
detecting breast cancer when used on women under 50, and greater than 80%
accurate in women 50 years and older.
"I am looking forward to working with Provista. Based on initial trial
results, we will conduct a larger, second round study with the goal of
integrating our Onko-Sure with Provista's existing BT panel of biomarkers
to further improve test accuracy and performance for cancer patients,"
stated Mr. Douglas MacLellan, CEO and Chairman of Radient
Pharmaceuticals. "This is a 'win-win' initiative and we are excited to
participate in this collaborative effort."
Radient Pharmaceuticals' subsidiary AMDL Diagnostics Inc. will provide
additional updates regarding their participation at ASCO via its
corporate website at www.radient-pharma.com.